Detalhe da pesquisa
1.
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Invest New Drugs
; 32(6): 1071-82, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25064374
2.
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
BMC Cancer
; 11: 124, 2011 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21477311
3.
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
BMC Cancer
; 11: 420, 2011 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21961653
4.
Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.
Mol Cancer Ther
; 7(4): 749-58, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18375822
5.
Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.
Leuk Res
; 30(4): 449-57, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16183118
6.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Mol Cancer Res
; 2(11): 606-19, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15561777
7.
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
J Control Release
; 105(1-2): 89-105, 2005 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15878792
8.
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Clin Cancer Res
; 10(7): 2512-24, 2004 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15073131
9.
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
Clin Cancer Res
; 10(2): 728-38, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14760096
10.
Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.
J Exp Ther Oncol
; 3(5): 261-71, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14696623
11.
Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
J Pharm Sci
; 102(1): 227-36, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23132529
12.
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.
PLoS One
; 8(3): e59597, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23555046
13.
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
Cancer Biol Ther
; 11(9): 826-38, 2011 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21358264
14.
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
J Control Release
; 144(3): 332-40, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20202473